GemVax & KAEL saw the highest growth of 0.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of GemVax & KAEL’s patent filings and grants. Buy the databook here.
GemVax & KAEL has been focused on protecting inventions in European Patent Office(EPO) with two publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent grants with nearly 100% of grants. The South Korea(KR), United States(US), World Intellectual Property Organization(WIPO), and European Patent Office(EPO) patent Office are among the top ten patent offices where GemVax & KAEL is filings its patents. Among the top granted patent authorities, GemVax & KAEL has 100% of its grants in European Patent Office(EPO).
DSM-Firmenich and Nestle could be the strongest competitors for GemVax & KAEL
Patents related to health & wellness and climate change lead GemVax & KAEL's portfolio
GemVax & KAEL has the highest number of patents in health & wellness followed by, climate change and sugar reduction. For health & wellness, nearly 43% of patents were filed and 50% of patents were granted in Q2 2024.
Food related patents lead GemVax & KAEL portfolio followed by cosmetics & toiletries, and skincare
GemVax & KAEL has highest number of patents in food followed by cosmetics & toiletries, skincare, bronchitis, and asthma. For food, nearly 4% of patents were filed and 33% of patents were granted in Q2 2024.
For comprehensive analysis of GemVax & KAEL's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.